(Q33804041)

29 July 2017

1 reference

title

New strategies for the management of AIDS-related CMV retinitis in the era of potent antiretroviral therapy (English)

1 reference

29 July 2017

anti-retroviral agent

0 references

author name string

Holland GN

series ordinal

1

1 reference

29 July 2017

1 December 1999

1 reference

Ocular Immunology and Inflammation

29 July 2017

1 reference

29 July 2017

7

1 reference

29 July 2017

3-4

1 reference

29 July 2017

179-188

1 reference

Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy

29 July 2017

1 reference

https://api.crossref.org/works/10.1076%2FOCII.7.3.179.4000

Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. CMV Retinitis and Viral Resistance Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1076%2FOCII.7.3.179.4000

Regression of cytomegalovirus retinitis associated with protease-inhibitor treatment in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1076%2FOCII.7.3.179.4000

Spontaneous and sustained resolution of CMV retinitis in patients receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1076%2FOCII.7.3.179.4000

Use of the ganciclovir implant for the treatment of cytomegalovirus retinitis in the era of potent antiretroviral therapy: recommendations of the International AIDS Society-USA panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1076%2FOCII.7.3.179.4000

Visual and anatomic outcomes associated with posterior segment complications after ganciclovir implant procedures in patients with AIDS and cytomegalovirus retinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1076%2FOCII.7.3.179.4000

Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1076%2FOCII.7.3.179.4000

Do all patients with CMV retinitis require life long anti-CMV therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1076%2FOCII.7.3.179.4000

Cytomegalovirus polymerase chain reaction viraemia in patients receiving ganciclovir maintenance therapy for retinitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1076%2FOCII.7.3.179.4000

Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1076%2FOCII.7.3.179.4000

AIDS and ophthalmology: a period of transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1076%2FOCII.7.3.179.4000

Effect of potent antiretroviral therapy on recurrent cytomegalovirus retinitis treated with the ganciclovir implant

21 January 2018

1 reference

https://api.crossref.org/works/10.1076%2FOCII.7.3.179.4000

Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1076%2FOCII.7.3.179.4000

Quantitative cytomegalovirus DNA level in the blood and its relationship to cytomegalovirus retinitis in patients with acquired immune deficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1076%2FOCII.7.3.179.4000

10.1076/OCII.7.3.179.4000

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10611726